http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 25 Feb 2026 16:05:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Press+Releases/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=UH85P7GQuXynVUs7myPVv8rGX93JWGRI0jYw1-KYkjDTzHYkreNJzaZG80IXMSASe3uqze81CJcDOc0D4yb2aimvaOVd9pLXEqBBbfkucUg=" rel="nofollow" target="_blank">Surrozen, Inc.</a> (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.</p> <p><strong>TD Cowen 46</strong><strong>th</strong><strong> Annual Healthcare Conference on Wednesday, March 4, 2026</strong></p> <p style="padding-left:40px;">Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time</p> <p>Interested parties may access the live audio webcast for the conference via http://www.streetinsider.com/Globe+Newswire/Surrozen+to+Present+at+Upcoming+Healthcare+Investor+Conference/26059647.html Wed, 25 Feb 2026 16:05:00 -0500 A.50100012 O.07579093 O.50352253 SRZN http://www.streetinsider.com/Press+Releases/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.</p> <p>The stock option was granted under Surrozen’s 2025 Equity Inducement Plan which provides for the http://www.streetinsider.com/Press+Releases/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html Mon, 23 Feb 2026 16:30:00 -0500 O.50352253 SRZN http://www.streetinsider.com/Press+Releases/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.</p> <p>The stock option was granted under Surrozen’s 2025 Equity Inducement Plan which provides for the http://www.streetinsider.com/Press+Releases/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html Mon, 23 Feb 2026 16:30:00 -0500 O.50352253 SRZN http://www.streetinsider.com/Globe+Newswire/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.</p> <p>The stock option was granted under Surrozen’s 2025 Equity Inducement Plan which provides for the http://www.streetinsider.com/Globe+Newswire/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html Mon, 23 Feb 2026 16:30:00 -0500 O.50352253 SRZN http://www.streetinsider.com/Globe+Newswire/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html <p>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.</p> <p>The stock option was granted under Surrozen’s 2025 Equity Inducement Plan which provides for the http://www.streetinsider.com/Globe+Newswire/Surrozen+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26043828.html Mon, 23 Feb 2026 16:30:00 -0500 O.50352253 SRZN http://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Surrozen+Inc.+%28SRZN%29+at+Overweight/26025434.html (Updated - February 19, 2026 6:10 AM EST) <p>Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Surrozen Inc. (NASDAQ: SRZN) with a Overweight rating and a price target of $40.00.</p><p>The analyst commented: "We are initiating coverage of SRZN at Overweight with a $40 price target. SRZN is a leader in Wnt biology, with foundational IP based on early work developing Wnt agonists and more recently advancing complex molecules towards the clinic in retinal diseases (Wnt/VEGF and Wnt/VEGF/IL-6 multi-functional molecules). SZN-8141 in both DME (PoS: 35%) and nAMD (PoS: 20%). At a net price comparable with precedent VEGF products (~$14.5K per year), http://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Surrozen+Inc.+%28SRZN%29+at+Overweight/26025434.html Thu, 19 Feb 2026 06:10:47 -0500 SRZN http://www.streetinsider.com/Analyst+Comments/Cantor+Fitzgerald+Starts+Surrozen+Inc.+%28SRZN%29+at+Overweight/26025434.html (Updated - February 19, 2026 6:10 AM EST) <p>Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Surrozen Inc. (NASDAQ: SRZN) with a Overweight rating and a price target of $40.00.</p><p>The analyst commented: "We are initiating coverage of SRZN at Overweight with a $40 price target. SRZN is a leader in Wnt biology, with foundational IP based on early work developing Wnt agonists and more recently advancing complex molecules towards the clinic in retinal diseases (Wnt/VEGF and Wnt/VEGF/IL-6 multi-functional molecules). SZN-8141 in both DME (PoS: 35%) and nAMD (PoS: 20%). At a net price comparable with precedent VEGF products (~$14.5K per year), http://www.streetinsider.com/Analyst+Comments/Cantor+Fitzgerald+Starts+Surrozen+Inc.+%28SRZN%29+at+Overweight/26025434.html Thu, 19 Feb 2026 06:10:47 -0500 SRZN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Li+Yang/26024189.html si-local-file:///var/storage/secattach/20260218/26024189.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Li+Yang/26024189.html Wed, 18 Feb 2026 18:47:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Li+Yang/26024189.html si-local-file:///var/storage/secattach/20260218/26024189.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Li+Yang/26024189.html Wed, 18 Feb 2026 18:47:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Williams+Charles+O/26024181.html si-local-file:///var/storage/secattach/20260218/26024181.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Williams+Charles+O/26024181.html Wed, 18 Feb 2026 18:45:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Williams+Charles+O/26024181.html si-local-file:///var/storage/secattach/20260218/26024181.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Williams+Charles+O/26024181.html Wed, 18 Feb 2026 18:45:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Parker+Craig+C/26024167.html si-local-file:///var/storage/secattach/20260218/26024167.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Parker+Craig+C/26024167.html Wed, 18 Feb 2026 18:40:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Parker+Craig+C/26024167.html si-local-file:///var/storage/secattach/20260218/26024167.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Surrozen%2C+Inc.DE+++++++++For%3A+Feb+17++Filed+by%3A+Parker+Craig+C/26024167.html Wed, 18 Feb 2026 18:40:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+BRAIDWELL+LP/26014527.html si-local-file:///var/storage/secattach/20260217/26014527.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+BRAIDWELL+LP/26014527.html Tue, 17 Feb 2026 16:49:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+BRAIDWELL+LP/26014527.html si-local-file:///var/storage/secattach/20260217/26014527.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+BRAIDWELL+LP/26014527.html Tue, 17 Feb 2026 16:49:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26014350.html si-local-file:///var/storage/secattach/20260217/26014350.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26014350.html Tue, 17 Feb 2026 16:44:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26014350.html si-local-file:///var/storage/secattach/20260217/26014350.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26014350.html Tue, 17 Feb 2026 16:44:00 -0500 O.50352253 SRZN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+STEMPOINT+CAPITAL+LP/26008605.html si-local-file:///var/storage/secattach/20260217/26008605.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Surrozen%2C+Inc.DE++++++++++++++++++++++Filed+by%3A+STEMPOINT+CAPITAL+LP/26008605.html Tue, 17 Feb 2026 10:02:00 -0500 O.50352253 SRZN